07.26.26 -- Rebuilding The U.S. Biotech Innovation Engine

Beware of shortcuts when it comes to scientific innovation. This week's selections from Life Science Leader focus on the importance of fundamentals, from basic science and clinical data collection, to planning and preparing for company growth. When it comes to basic science, the NIH and the NSF are unsung (and underfunded) heroes, building the infrastructure of the future, writes repeat biotech founder Dietrich Stephan. The pressure of quarterly earnings and basic science don’t mix.

In the psychedelic drug development realm, a recent Executive Order helps to clarify regulations and de-risk development. But that doesn’t mean developers can bypass rigorous clinical data collection and manufacturing standards, writes Enveric Biosciences’ Joseph Tucker, Ph.D.

For long-term success in the commercial market, biotechs should start building product value through HEOR and payer engagement in parallel with late-stage clinical development, explains CervoMed’s Matt Winton, Ph.D., on the Business of Biotech.

Check out a curated selection from our partners, below, and thanks as always for reading.

Ben Comer                      
Chief Editor, Life Science Leader

Advarra examines how proactive protocol planning can prevent avoidable amendments and improve long-term trial performance before the first patient is enrolled.

Worldwide Flex explores how cross-functional collaboration and standardized processes strengthen the foundation for reliable clinical data throughout study execution.

Cytiva highlights how early manufacturing decisions can determine future scalability, consistency, and regulatory readiness for cell therapy programs.

EmVenio Clinical Research considers how expanding trial access through community-based models still requires rigorous oversight and compliance at every stage of research.

Paradigm Health looks at how improving U.S. patient access can strengthen regulatory confidence and trial relevance in an evolving approval environment.

CSS explores how data-driven recruitment strategies are replacing broad outreach with greater precision and efficiency in patient enrollment.

Block Clinical Inc. examines how modern payment infrastructure is becoming a critical enabler of efficient trial execution as research grows more complex and decentralized.